The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes

Direct-to-consumer (DTC) genetic testing services raise scientific, regulatory and ethical questions. A report was prepared by consultation with an expert Working Group and published by the academies of science (European Academies of Science Advisory Council, EASAC) and medicine (Federation of Europ...

Full description

Saved in:
Bibliographic Details
Published in:European journal of human genetics : EJHG 2013-07, Vol.21 (7), p.703-707
Main Authors: Fears, Robin, ter Meulen, Volker
Format: Article
Language:English
Subjects:
Clinical medicine
Councils
Data processing
Disease
Ethics
Europe
Female
Genetic Diseases, Inborn - diagnosis
Genetic Diseases, Inborn - genetics
Genetic Diseases, Inborn - pathology
Genetic markers
Genetic screening
Genetic Testing
Genetics
Genomes
Genomics
Humans
Medical personnel
Medicine
Policy
Pregnancy
Prenatal Diagnosis
Professionals
Public Health
Quality Control
Regulation
Science
Translation
Working groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct-to-consumer (DTC) genetic testing services raise scientific, regulatory and ethical questions. A report was prepared by consultation with an expert Working Group and published by the academies of science (European Academies of Science Advisory Council, EASAC) and medicine (Federation of European Academies of Medicine, FEAM). This report reviews current scientific evidence, ascertains the principles that should underpin the options for action by policy-makers, and discusses the potential for devising proportionate and flexible regulation that enables future innovation, taking account of the work of other expert groups, most notably the European Society of Human Genetics. EASAC-FEAM concluded that DTC genetic testing has little clinical value at present, and expresses especial caution in several specific respects, for example relating to testing for high penetrance, serious disorders, prenatal screening, nutrigenomic and pharmacogenetic testing. It was emphasised that regulation must be on the basis that claims about the link between genetic marker and disease are scientifically valid. Other key issues to address include quality assurance (that includes the professional interpretation of results), transparent supply of accurate information, consideration of the implications for established health services, and clarification of consent procedures for any use of data for research purposes. There are important implications: for the European Commission, in revising the Directive on In Vitro Diagnostic Medical Devices; for professional bodies, in supporting training and guideline development; for the broader research community, in generating the evidence base; and for the public health community, in improving the routine translation of research advances into clinical practice.
ISSN:1018-4813
1476-5438
DOI:10.1038/ejhg.2012.238